The K/BxN model results further suggest that the problematic maintenance of Th17 cells in middle-aged compared to young individuals may further contribute to the ineffectiveness of anti-IL-17 therapy in patients with RA, who are mostly middle-aged and older individuals. The gene discussed is IL17A; the disease is rheumatoid arthritis.